Background: Influenza virus triggers severe asthma exacerbations for which no adequate treatment is available. It is known that IL-33 levels correlate with exacerbation severity, but its role in the immunopathogenesis of exacerbations has remained elusive. Objective: We hypothesized that IL-33 is necessary to drive asthma exacerbations. We intervened with the IL-33 cascade and sought to dissect its role, also in synergy with thymic stromal lymphopoietin (TSLP), in airway inflammation, antiviral activity, and lung function. We aimed to unveil the major source of IL-33 in the airways and IL-33-dependent mechanisms that underlie severe asthma exacerbations. Methods: Patients with mild asthma were experimentally infected with rhinovirus. Mice were chronically exposed to house dust mite extract and then infected with influenza to resemble key features of exacerbations in human subjects. Interventions included the anti-IL-33 receptor ST2, anti-TSLP, or both. Results: We identified bronchial ciliated cells and type II alveolar cells as a major local source of IL-33 during virusdriven exacerbation in human subjects and mice, respectively. By blocking ST2, we demonstrated that IL-33 and not TSLP was necessary to drive exacerbations. IL-33 enhanced airway hyperresponsiveness and airway inflammation by suppressing innate and adaptive antiviral responses and by instructing epithelial cells and dendritic cells of house dust mite-sensitized mice to dampen IFN-b expression and prevent the T H 1-promoting dendritic cell phenotype. IL-33 also boosted luminal NETosis and halted cytolytic antiviral activities but did not affect the T H 2 response. Conclusion: Interventions targeting the IL-33/ST2 axis could prove an effective acute short-term therapy for virus-induced asthma exacerbations. (J Allergy Clin Immunol 2019;143:1355-70.) 
Acute worsening of asthma symptoms (exacerbations) paralleled by exaggerated airway inflammation represents a major burden to patients, health care providers, and the economy. Typically, exacerbations are treated by enhanced dosing of inhaled corticosteroids, 1 but severe exacerbations can be insensitive to inhaled and even systemic corticosteroids and thus constitute a major unmet medical need. 2, 3 Rhinovirus, respiratory syncytial virus, and influenza A cause up to 80% of asthma exacerbations in children and 50% of exacerbations in adults. [4] [5] [6] Both defective type I and type III interferon antiviral responses [7] [8] [9] and exaggerated T H 2 responses 10 have been considered main drivers of asthma exacerbations.
Recent studies have indicated that the alarmin IL-33, an IL-1 family member cytokine, is enhanced in asthmatic patients 11 and released in nasal lining fluid during virus-induced exacerbations, correlating with the inflammatory response and clinical symptoms. 10 Similar enhanced IL-33 production in lung tissue was shown in house dust mite (HDM)-sensitized mice infected with influenza X31, a mouse model of severe influenza-induced asthma exacerbation that recapitulates all key features of the human disease, including the corticosteroid insensitivity of the inflammatory process. 2, 12 We hypothesized that IL-33 drives this influenza-induced asthma exacerbation. IL-33 acts through a receptor complex known as ST2 and IL-1 receptor accessory protein to initiate myeloid differentiation response gene-88-dependent inflammatory pathways. 13, 14 Because the IL-33 receptor complex is present on a range of innate and adaptive immune cells, IL-33 can exert pleiotropic effects. [15] [16] [17] [18] [19] [20] Therefore we analyzed in detail its role in inflammatory processes during influenza-induced exacerbation and on various cell types, among which are innate lymphoid cells. Furthermore, because IL-33 was found to drive the severity of respiratory syncytial virus infections in naive mice, 21 we also investigated the effect of IL-33 in naive versus HDM-sensitized mice on influenza infection. Finally, we also determined the role of thymic stromal lymphopoietin (TSLP), a mediator produced by bronchial epithelial cells (ECs) that synergizes with IL-33, [22] [23] [24] during virus-induced exacerbation of experimental asthma.
We demonstrated that IL-33 drives this increased airway hyperresponsiveness (AHR) and viral replication and that both lymphoid and myeloid populations infiltrate into the airway lumen and parenchyma, whereas TSLP was redundant in this model. IL-33 suppressed T H 1-like innate antiviral responses without affecting T H 2-like responses and promoted NETosis during asthma exacerbations. Importantly, IL-33 instructed airway ECs and dendritic cells (DCs) to dampen ifnb expression and prevented the development of a T H 1-promoting DC phenotype. Therefore blocking IL-33 could prove a novel acute therapy against virus-induced asthma exacerbations.
METHODS
Detailed methods are provided in the Methods section in this article's Online Repository at www.jacionline.org.
Mice, allergen, virus, and treatments
All experiments described were approved by the Animal Research Ethics Board of the Academic Medical Center (protocol nos. DSK102810 and DSK49-AA) in adherence to the National Institutes of Health's ''Guide for the care and use of laboratory animals'' performed according to institutional guidelines and European Union and Netherlands legislation.
Male 8-week-old C57BL/6J mice purchased from Charles River Laboratories (Wilmington, Mass) were housed under specific pathogen-free conditions and maintained on a 12-hour light-dark cycle with access to food and water ad libitum. Groups of C57BL/6J mice were randomly assigned (simple randomization) to treatment for 5 days a week for 5 consecutive weeks with either the aeroallergen HDM (Greer Laboratories, Lenoir, NC) 25 or NaCl through intranasal administration. Lyophilized HDM extract was resuspended in sterile NaCl at a concentration of 5 mg of protein/mL, and 25 mg (5 mL) of protein per dose per mouse was administered intranasally in a final volume of 20 mL (in NaCl) in mice lightly anesthetized with isoflurane. The H3N2 influenza A virus HK X31 stocks and viral titers were obtained by infecting Madin-Darby Canine Kidney cells, as described previously. 12 The viral stock suspension was diluted in NaCl, and animals (lightly anesthetized with isoflurane) received intranasal 20 TCID 50 (50% of the tissue culture infective dose) in 50 mL.
Anti-mouse ST2 (aST2), anti-mouse TSLP (aTSLP), and the isotype control antibodies, which were kindly provided by Drs Dirk Smith and Michael C. Comeau, 26 were resuspended in sterile NaCl and 150, 350, or 250 mg of protein in 100 mL per mouse, respectively, and administered when indicated through the intraperitoneal route. Prednisone (Sigma-Aldrich, St Louis, Mo) was diluted in sterile NaCl and 5 mg/kg in 100 mL and administered separately through the intraperitoneal route. Prednisone, aST2, or aTSLP were given at separate time points because of their intrinsic pharmacodynamic and pharmacokinetic characteristics.
These treatments are all therapeutic and not prophylactic. The different schedules for each treatment are based on extensive pilot studies on HDMsensitized mice and X31-infected mice (Respiratory R&D, GlaxoSmithKline, Stevenage, United Kingdom; unpublished data were provided kindly by Robert Shaw) and were expected to be efficacious, with evident beneficial anti-inflammatory effects within the shortest period after administration and without eliciting serious side effects (ie, body weight loss and dysregulation of immune function).
AHR measurements
AHR responses were assessed at the indicated time points based on methacholine-induced airflow obstruction in conscious mice placed in a whole-body plethysmograph (Buxco Electronics, Troy, NY), as described previously. 12 
Mouse trachea EC analysis
Tracheas from euthanized mice were longitudinally dissected, and ECs were collected by means of gentle brushing with a sterile RNase-free cotton swab and vigorously resuspended in sterile saline. Cells were pelleted at 240g for 10 minutes at 48C and used for RNA extraction with TRIzol (Thermo Fisher Scientific, Waltham, Mass), according to the manufacturer's instructions.
Samples were analyzed for ifnb expression by using quantitative PCR (qPCR; see the corresponding paragraph) and for il33 and tslp expression by using the Affymetrix GeneChip Mouse Gene 2.1 ST Array (Affymetrix, Santa Clara, Calif) and analyzed as detailed in the Methods section in this article's Online Repository. Details on collection and processing of other murine samples are provided in the Methods section in this article's Online Repository.
In vivo rhinovirus-16 challenge in healthy control subjects and asthmatic patients Primary bronchial epithelial cells (PBECs) were obtained from 17 atopic patients with mild asthma who were steroid naive and 4 nonatopic, nonasthmatic healthy subjects without a recent infection and no serumneutralizing antibodies to rhinovirus-16 (RV16) at screening (< _1/4), before and 6 days after RV16 exposure (Sabogal Pineros et al 27 ; Ravi et al 28 ). Clinical characteristics of asthmatic patients and healthy subjects recruited by using strict inclusion and exclusion criteria are reported in Table E1 in this article's Online Repository at www.jacionline.org.
The study protocol was approved by the Medical Ethics committee of the Academic Medical Center, according to institutional guidelines and European Union and Netherlands legislation. All subjects provided written informed consent and were successfully infected intranasally with 10TCID 50 RV16 in 750 mL based on Wisconsin Upper Respiratory Symptoms Survey scores and/or nasal swab viral load and/or seroconversion. Respiratory symptom scores were recorded, and bronchoscopy was performed at baseline and 6 days after RV16 inoculation.
Human PBEC analysis
Human PBECs were collected by means of bronchial brushing during bronchoscopy and directly dissolved in 1 mL of TRIzol (Invitrogen, Thermo Fisher Scientific). RNA was isolated, processed, and sequenced as detailed in the Methods section in this article's Online Repository at www.jacionline.org.
Immunostaining
Mouse lungs were collected at the indicated time points after infection without performing bronchoalveolar lavage (BAL) and fixed for 1 day with 4% paraformaldehyde in PBS. Lung tissues were paraffin embedded and stained with anti-IL-33, as detailed in the Methods section in this article's Online Repository. For determination of neutrophil extracellular trap (NET) immunoreactivity, lung sections were stained in blocking buffer with rabbit antibodies to citrullinated histone H3 (H3Cit; ab5103; Abcam, Cambridge, United Kingdom) and with goat antibodies to myeloperoxidase (MPO; R&D Systems, Minneapolis, Minn) for 2 hours at 378C. After washing samples with PBS, secondary donkey anti-rabbit and anti-goat IgG antibodies conjugated with Alexa Fluor 568 (Thermo Fisher) and Alexa Fluor 488 (Thermo Fisher) were added in blocking buffer containing 49-6-diamidino-2-phenylindole dihydrochloride (R&D Systems) and incubated for 2 hours in the dark. Finally, samples were mounted with 10 mL of ProLong Antifade reagent (Thermo Fisher) on glass slides and stored at room temperature in the dark overnight.
For staining of human PBECs with anti-IL-33, brush biopsy specimens were collected during bronchoscopy in 1 mL of sterile NaCl, and cytospins were prepared (2 minutes at 550 rpm), fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Tween 20 for 10 minutes, and incubated for 1 hour with 10% goat serum to block aspecific binding sites. Slides were incubated with 1:250 dilution of anti-IL-33 monoclonal mouse IgG 1 (Nessy-1; #ALX-804-840/1) or mouse isotype control (#X0931; DAKO, Glostrup, Denmark) for 1 hour and subsequently with Alexa Fluor 568 goat antimouse (#A-11004) for 1 hour and treated with 49-6-diamidino-2-phenylindole dihydrochloride prolong gold anti-fade reagent (Thermo Fisher).
All samples were analyzed by using fluorescence microscopy with standard filter sets. Controls were stained with secondary antibody only, and nonspecific fluorescence staining was not detected when secondary antibodies were tested alone. Images were acquired on a Leica TCS SP8-SMD confocal microscope (Leica, Wetzlar, Germany). 
Flow cytometric analysis and sorting

Ex vivo cell stimulation for intracellular cytokine staining
Freshly isolated lung cells were stimulated for 6 hours with UV-inactivated influenza X31 (20 TCID 50 /mL), Der p 1 (0.5 mg/mL), and LPS (0.5 mg/mL) or with phorbol 12-myristate 13-acetate (10 ng/mL; Sigma) and ionomycin (500 nmol/L; Merck, Whitehouse Station, NJ) in the presence of GolgiPlug (BD) for the final 4 hours of culture. A Cytofix/Cytoperm kit (BD) was used for cell permeabilization, staining, and subsequent washing. The following antibodies (clone ID in parentheses) were used at concentrations recommended by the manufacturers: IL-21 (FFA21), IL-13 (eBio13A), IFN-g (XMG1.2) (all from eBioscience), IL-17 (TC11-18H10.1) (from BioLegend), and IL-6 (MP5-20F3; from BD Biosciences). Data were acquired on an LSRFortessa or FACSCanto II instrument and were analyzed with FlowJo software (TreeStar, Ashland, Ore).
Gene expression assessment by using qPCR Determination of viral outgrowth by using qPCR Viral load was determined by using real-time qPCR in lung cell suspension, as described previously. 12 The viral load present in a sample was calculated by using a standard curve of particle-coated influenza virus included in every assay run. The following primers were used: 59-GACAAGACCAATCCTGT CACYTCTG -39 (forward), 59-AAGCGTCTACGCTGCAGTCC -39 (reverse), and 59-TTCACGCTCACCGTGCCCAGTGAGC -39 (50-FAMlabeled probe).
Histopathologic analysis
Left lungs from 4 additional animals per group not having undergone BAL and not used for fluorescence-activated cell sorting analysis were harvested at the indicated time points, fixed overnight in 10% formalin, and embedded in paraffin. Sections (4 mm) were stained with hematoxylin and eosin and periodic acid-Schiff. Multiple images of the primary airway were taken by using OpenLab software (version 3.0.3; Improvision, Coventry, United Kingdom) with a camera and microscope (Leica Microsystems). 
Cytokine and chemokine analysis
Data analysis
Data are expressed as indicated. Results were interpreted with Prism 5 software (GraphPad Software, La Jolla, Calif). Differences were considered statistically significant at a P value of less than .05. Experiments were conducted with 4 to 6 mice per group per time point, and data are representative of 4 independent replicates unless indicated differently. Numbers of mice used are indicated in figure legends.
RESULTS
IL-33 drives AHR, inflammation, and T H 2 immunity in patients with experimental chronic allergic asthma
To test the hypothesis that IL-33 drives allergic airways inflammation and asthma exacerbations, we first addressed the role of IL-33 in sustaining chronic airway inflammation in HDMsensitized mice (see Fig E1, A, in this article's Online Repository at www.jacionline.org). 25 Treatment with an anti-ST2 antibody (aST2) abrogated AHR (Fig 1, A) to a similar extent as systemic corticosteroids (prednisone). Similarly, aST2 and prednisone significantly reduced numbers of total BAL fluid cells, as well as numbers of total and inflammatory (CD101 1 ) 29 eosinophils, neutrophils, alveolar macrophages, and CD11b
1 DCs in BAL fluid (Fig 1, B) . In lung parenchyma aST2 and prednisone reduced numbers of CD4 1 lymphocytes and invariant natural killer T (iNKT) cells and efficiently abrogated intracellular IL-13 in both innate and adaptive lymphocytes. Notably, only aST2 (not prednisone) reduced the numbers of natural killer (NK) cells and efficiently abrogated intracellular IL-17 but not IFN-g (see Fig E2 in this article's Online Repository at www.jacionline.org). Importantly, type 2 innate lymphoid cells (ILC2s) and natural cytotoxicity receptor (NCR) 1 type 3 innate lymphoid cells (ILC3s) were corticosteroid resistant. Numbers of lung ILC2s and NCR 1 ILC3s were not affected by aST2, but IL-33 signaling drove IL-13 expression in ILC2s and suppressed intracellular IFN-g in NCR 1 ILC3s (Fig 1, B) .
Lung ECs are a major source of IL-33 in virus-induced asthma exacerbation in mice and human subjects
Next, we analyzed the presence of IL-33 and the innate lymphocyte profile during virus-induced asthma exacerbations. Bronchial ECs, predominantly ciliated cells, from asthmatic patients 6 days after in vivo inoculation with RV16 showed enhanced expression of IL-33 protein (Fig 2, A) . Even 6 days after infection, IL33 gene expression was still significantly increased in PBECs from patients with mild asthma compared with those from healthy control subjects (Fig 2, B) , supporting findings in the mouse model of severe asthma exacerbation (see Fig E1, B) 12 in which influenza enhanced il33 transcription in tracheal ECs compared with control cells (HDM or NaCl/X31 at day 4 after influenza; see Fig E3 , A, in this article's Online Repository at www.jacionline.org). Notably, IL33 gene expression levels in PBECs from patients with mild asthma were not different before and 6 days after RV16 infection (data not shown). In lungs of HDM/X31-treated mice, the major source of IL-33 are type II alveolar cells (Fig 2, C) , where IL-33 loss, which is likely associated with its release, 30 is restricted to patchy areas of aggravated inflammation (cells dense areas). Gradual but not complete loss of IL-33 in cell-dense areas occurred on influenza infection and was enhanced by HDM chronic exposure, resulting in cell-dense areas with complete lack of IL-33 (Fig 2, C and D) .
ILC2 numbers are not enhanced and do not correlate with disease severity in a mouse model of influenza-induced asthma exacerbation
Previously, we have shown that numbers of myeloid innate cells (eosinophils and neutrophils) and lymphocytes were increased during influenza-induced asthma exacerbations. 12 Given the crucial role of IL-33 in driving innate immune responses, 31 we extended our earlier 12 analyses to other innate immune cells. Compared with HDM-sensitized mice, ILC2 counts were not increased after influenza infection at any time in BAL fluid or lung parenchyma (Fig 2, E) or in spleen cells and mLNs (data not shown). ILC2 numbers did not correlate with any key feature of asthma exacerbations, such as AHR, BAL fluid inflammatory cell counts, or lung IL-33 levels (data not shown). In the early phase of the response to influenza in HDM-sensitized mice, numbers of BAL fluid NK cells were enhanced, as were iNKT cells and basophils in lung parenchyma. Two subsets of ILC3s, NCR 1 ILC3s and CD4 1 lymphoid tissue inducer (LTi) cells, [32] [33] [34] respectively, were significantly reduced in lung tissue at day 1 and day 6 and increased at day 6 after infection (see Fig E3, B) . Together, these results show that experimental severe asthma exacerbations do not correlate with robust changes in ILC2 numbers within the airways but instead correlate with early decreased NCR 1 ILC3 numbers and enhanced basophil, NK, iNKT, and LTi numbers.
IL-33 is necessary to drive influenza-induced exacerbation of experimental asthma, whereas TSLP is redundant
The cytokine TSLP, which is proposed to promote T H 2 airway inflammation and induce corticosteroid resistance in a subset of innate lymphocytes, is known to synergize with IL-33. 23, 35, 36 TSLP protein levels were increased in lung parenchyma of HDM-sensitized mice (independent of influenza infection) compared with that of naive mice between days 1 and 4 after influenza infection (see Fig E4, A, in this article's Online Repository at www.jacionline.org). In contrast, TSLP protein levels significantly increased 8 days after infection in naive mice but not in HDMsensitized mice. Interestingly, transcriptome analysis of ECs revealed no differences between groups with respect to tslp mRNA expression (see Fig E4, B) . tslp mRNA expression was not determined in lung homogenates and specific immune cells.
Next, HDM/X31 mice were treated with either aST2 or aTSLP 3 days before influenza infection and every 3 days thereafter to dissect the individual or combinatorial contributions of IL-33 and TSLP in driving the exacerbation. In addition, one group received isotype control antibodies and another group received both aST2 and aTSLP antibodies to address the potential synergism between IL-33 and TSLP (see Fig E1, C) . Blocking both pathways attenuated AHR changes at day 7 after infection. Interestingly, aTSLP worsened AHR compared with that seen in the other groups (Fig 3, A) . Body weight loss was markedly reduced on treatment with aST2 or Fig 1, A, Data represent means 6 SEMs (2-way ANOVA followed by the Bonferroni posttest). *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups. Fig 1, B , Data represent means 6 SEMs (t test). *P < .05, **P < .01, and ***P < .001 for comparison between indicated groups. Iso, Isotype control; Pred, prednisone.
aST2 in combination with aTSLP compared with aTSLP only and an isotype control (Fig 3, B) . Viral load was reduced partially in mice treated with aTSLP at day 6 but more markedly on aST2 treatment at day 8 after infection compared with that in both the isotype controls and those treated with both antibodies (Fig 3, C) .
We extensively evaluated the inflammatory infiltrate in BAL fluid, lung parenchyma, and mLNs. Either aST2 or aST2 in combination with aTSLP significantly reduced numbers of total BAL fluid cells, eosinophils, neutrophils, alveolar macrophages, CD4
1 cells, CD8 1 cells, B lymphocytes, basophils, and NK cells on days 6 and 8. CD11b
1 conventional dendritic cells (cDCs), iNKT cells, ILC2, NCR 1 ILC3s, and LTis were inhibited on either one of these days (Fig 3, D) .
Interestingly, blocking the IL-33 pathway did not affect the inflammatory eosinophil population (CD101 Fig E5, A, in this article's Online Repository at www.jacionline.org). Furthermore, aST2 attenuated inflammatory cells in lung parenchyma (see Fig E5, B) , whereas CD101
1 or CD86 1 MHC class II 1 eosinophils were not affected (see Fig E5, C) . aST2 also attenuated inflammatory cells at day 6 in mLNs (see Fig E6, A, in this article's Online Repository at www.jacionline.org), which was also clearly reflected macroscopically (Fig 3, E) . aTSLP did not affect cell numbers in BAL fluid, lung tissue, and mLNs, although there appeared to be impaired immune trafficking and a partial retention of myeloid and lymphoid cell subsets in mLNs (see Fig E6, A) , which was clearer in the spleen (see Fig E6, B) .
Thus IL-33, but not TSLP, drives experimental asthma exacerbation, enhances airway inflammation, and increases viral load in the lung, resulting in a more severe response to influenza in HDM-sensitized mice. In contrast, TSLP did not markedly contribute to inflammatory cell numbers but reduced AHR synergistically with IL-33. Unexpectedly, TSLP appeared to direct immune trafficking in lymphoid organs (see Fig E6) .
IL-33 drives both early and late innate and adaptive airways inflammation in influenza-induced exacerbation of experimental asthma
Previously we have shown that the early (14 hours to 2 days after infection) immune response of allergic mice infected with influenza was clearly distinct from that of control mice. 12 This led us to a focus on IL-33-dependent events shortly after viral challenge (see Fig E1, D) . aST2 treatment was sufficient to significantly reduce AHR at days 3 and 6 after infection (Fig 4, A) but not at day 7 after infection (Fig 3, A) and resulted in reduced numbers of BAL fluid total cells, eosinophils, neutrophils, alveolar macrophages, total lymphocytes (data of latter not shown), CD4
1 T cells, and iNKT cells at most early time points (Fig 4, B) . Biphasic reduction at 14 hours to 1 day and again at 6 to 8 days after infection was seen for BAL fluid basophils, NCR 1 ILC3s, LTi cells, and NK cells. Interestingly, the ILC2 population was not affected at early time points (Fig 4, B) .
In mLNs aST2 decreased numbers of myeloid and lymphoid cell populations in a specific biphasic kinetic response (1 and 6 days after infection) in comparison with control values (see Fig  E7, A, in this article's Online Repository at www.jacionline.org), as opposed to an early short cellular decrease in lung parenchyma (see Fig E7, B) . We confirmed the results for days 6 and 8 after infection, as reported in Fig 3. The resolution of airway inflammation and pathology (ie, mucus overproduction) by blocking IL-33 signaling was also strikingly evident based on histologic examination of lungs (8 days 
IL-33 halts innate and adaptive antiviral immunity and boosts NETosis but does not affect T H 2 response in patients with influenza-induced asthma exacerbations
We examined whether cellular responses were paralleled by changes in inflammatory mediator and cytotoxic profiles within lung parenchyma and BAL fluid. Treatment with aST2 resulted in an early significant reduction in BAL levels of the cytokine IL12p40 (14 hours and day 1 after infection) and later (day 4 after infection) for the chemokines macrophage inflammatory protein (MIP) 1a and MIP-1b and the cytokine IL-6 (day 6 after infection); however, levels of the T H 2 cytokine IL-5 were not significantly reduced (see Fig E7, C) . In lung homogenates IL-33 levels were markedly reduced in the early phase (14 hours to day 1 after infection) after aST2 (Fig 4, D) . Notably, aST2 increased concentrations of IL-1a (data not shown) and IL-1b, IL-23, IL-22 (cytokines involved in lung tissue repair processes) and the T H 1 cytokines IL-21, IL-12p70, IFN-g (day 2 after infection), IL-12p40 (day 8 after infection), and RANTES (14 hours and days 4-6 after infection ; Fig 4, D; see Fig E7, D) . This inhibitory effect of IL-33 on T H 1 cytokines, IL-22, and IL-23 is also confirmed by the negative correlations in exacerbating mice (see Fig E7, E) . Importantly, IL-5 and IL-13, together with IL-9 (involved in T H 2 inflammation and lung remodeling), were not affected by aST2, whereas levels of IL-31, which is involved also in limiting T H 2 inflammation, 37 were significantly reduced (day 6 after infection). Levels of the chemokines monocyte chemoattractant protein 1/CCL2, MIP-1a, MIP-1b, KC (cytokine- ) at day 7 after infection. B, aST2, but not aTSLP, protects from severe response to X31 infection, as indicated by body weight loss (0% and 13%, respectively) at 8 days after infection. C, Influenza viral load in lung homogenates at days 6 and 8 after infection. D, Total cell and differential immune cell counts in BAL fluid on days 6 and 8 after infection. E, mLN sizes at day 8 after infection. Data are representative of 4 replicates of independent experiments for groups of 4 or 6 mice. Fig 3, A and B , Data represent means 6 SEMs. *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups, 2-way ANOVA followed by the Bonferroni posttest. Fig 3, C and D , Data represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups, t test.
induced neutrophil-attracting chemokine) (all at day 6 after infection), and eotaxin (days 1-2 after infection) were significantly induced by aST2 compared with control values (see Fig E7, D) . Strikingly, intracellular IL-13 production was not reduced by aST2 in CD4 1 or CD8 1 T cells from lungs of exacerbating mice, whereas T H 1 cytokine levels (IFN-g and IL-21) were increased in both cell subsets (day 6 after infection; see Fig E7, F) .
Together (Fig 1) and influenzachallenged HDM-sensitized mice, the effect of IL-33 appears to depend on the local environment in which it is released.
IL-33 suppresses antiviral immunity to influenza by instructing ECs and DCs of HDM-sensitized mice
We hypothesized that IL-33 silences T H 1 cell-mediated immunity through induction of OX40L on DCs and reduction in IL12p35 production involved in T H 2 cell polarization 38 and T H 1 immunity promotion, 39, 40 respectively. Importantly, we demonstrated that in exacerbating mice with increased IL-33 levels, flow-sorted lung moDCs and CD11b 1 cDCs upregulated levels of OX40L and the costimulatory molecule CD86 (days 4 and 6 after infection) compared with DCs from mice that received aST2 (Fig 4, E) . On the contrary, IL-33 downregulated il12p35 mRNA in flow-sorted lung moDCs (Fig 4, F) . Thus blocking IL-33 signaling was able to reduce OX40L and restore il12p35 expression. These data demonstrate that the aST2/IL-33 axis determines skewing of the T H 2/T H 1 polarization of the immune response promoted by DCs.
Consistent with previous human studies that demonstrated a negative correlation between innate interferon levels and asthma exacerbation, 41, 42 in ECs from chronically HDM-exposed mice, we found a deficient IFN-b response on influenza infection (day 4 after infection) compared with that seen in control mice (see Fig E10 in this article' s Online Repository at www. jacionline.org). Surprisingly, inhibition of IL-33 signaling restored ifnb expression in ECs and CD11b 1 cDCs sorted from lungs of exacerbating mice (Fig 4, G) . Therefore we concluded that IL-33 halts the innate antiviral response not only in immune cells but also in structural lung cells.
IL-33 also significantly enhanced levels of mediators involved in recruitment of lymphocytes and neutrophils (RANTES, monocyte chemoattractant protein 1, MIP-1a, MIP-1b, KC, and IL1b), which can exert cytotoxic antimicrobial functions when activated.
18,43 IL-33 attenuated antiviral responses of lymphocytes and neutrophils of HDM/X31 mice, as reflected by reduced levels of granzyme A, elastase, and MPO (day 6 after infection) in lung parenchyma (where viral replication occurs). However, IL-33 boosted granzyme A and elastase levels in BAL fluid from exacerbating mice, which is suggestive of enhanced cytotoxic activity in the airway lumen and potentially harmful for mucosal barrier integrity (Fig 4, H) . This observation is of particular interest because neutrophil-derived elastase and MPO in the airway lumen are reported to be associated with NETosis-dependent airflow obstruction and asthma exacerbation (Fig 4, I) . 44, 45 NETs were abundantly present in the lungs of exacerbating mice at day 4 after infection. Treatment with aST2 abolished NET and MPO/Cit-H3 proteins detection at the mucosal surface.
Together, these findings indicate that IL-33 reduced antiviral responses of lymphocytes and neutrophils in the parenchyma and promoted NETosis and lytic activity at the mucosal surface. 46, 47 However, further mechanistic in vitro studies are required to substantiate these findings.
IL-33 drives innate and adaptive airway inflammation and suppresses antiviral immunity to influenza in naive mice
aST2 was administered 3 days before influenza infection and every 3 days thereafter to address whether IL-33 also attenuated antiviral and T H 1 responses during acute influenza infection in naive mice. Control mice received isotype control antibodies, and all mice were analyzed at days 4, 6, and 8 after infection (see Fig E1, E) . No difference in body weight loss was noted between aST2-treated and control mice (see Fig E11, A, in this article's Online Repository at www.jacionline.org) and AHR did not differ (data not shown), but aST2-treated mice had markedly reduced viral loads (Fig 5, A) . Furthermore, total BAL fluid cell numbers (day 6 after infection) and eosinophil, neutrophil (days
4-6 after infection), alveolar macrophage (day 6 after infection), T-lymphocyte (day 8 after infection), NK and iNKT cell (days 6-8 after infection), NCR
1 ILC3 (days 4-8 after infection; Fig 5, B) , and basophil (data not shown) numbers, but not ILC2 numbers (data not shown), were reduced by aST2.
In lung parenchyma aST2 significantly reduced ILC2, NK, iNKT, and neutrophil numbers (day 8 after infection) compared with those in control animals (see Fig E11, B) . In parallel, aST2 increased levels of IL-21, IL-22, IL-23, IL-31, and IFN-g in lung parenchyma (Fig 5, C) and significantly reduced lymphocyte-or neutrophil-dependent cytotoxic enzyme concentrations in BAL fluid (Fig 5, D) . These findings correspond to our observations for aST2 in HDM-sensitized mice infected with X31 (Fig 4) in that IL-33 dampens antiviral responses, resulting in prolonged and aggravated airway inflammation underlying the asthma exacerbation.
DISCUSSION
Despite evidence that viral load correlates with disease severity, virus-induced asthma exacerbations are considered mostly driven by amplified T H 2 responses rather than inefficient T H 1 antiviral responses. 48,49 IL-33 also suppressed ifnb expression in both structural cells and CD11b 1 cDCs, which provide the earliest response to a viral challenge (Fig 4, G) . Fig 4, E-I) replicates of independent experiments with 4 mice per group. Fig 4, A and B , Data represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for the comparison between the HDM/X31 plus aST2 and HDM/X31 groups, 2-way ANOVA and the Bonferroni posttest. Fig 4, D-H , Data represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups, t test.
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lumen. In line with these attenuated innate and adaptive T H 1-like and cytotoxic responses, the influenza load increased in lung tissue of HDM-sensitized and naive mice in an IL-33-dependent manner (Figs 3, C, and 5, A) . Some of the mechanisms by which IL-33 dampens the antiviral responses in this asthma exacerbation model are elucidated here. We found that IL-33 severely impaired il12p35 expression, the predominant cytokine driving T H 1 cell development, whereas it upregulated the T H 2-driving OX40L expression. 39, 40 Type I interferons like IFN-b stimulate the expression of many genes, which induce an antiviral state to limit viral replication. IFN-b also enhances the antiviral mechanism and cytolytic activity of T cells by inducing granzyme expression. 50 Several reports have indicated that both bronchial ECs and circulating immune cells from asthmatic patients are defective in innate interferon production. 41, 51 However, these observations are disputed because other groups did not find defective innate interferon production. 52 Our findings could provide an explanation for this because the effect of IL-33 on cells can be attenuated after prolonged in vitro culturing of the sampled cells. In a very recent article, it was proposed that IL-33 could predispose to rhinovirusinduced exacerbation in cockroach-sensitized and pneumonia mice per group and represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups, t test.
virus-infected mice. Although no data were presented that rhinovirus indeed induced an asthma exacerbation with its fundamental characteristics (increases of AHR, lung pathology, lymphocyte infiltrates, and viral load), treatment with an anti-IL-33 antibody resulted in reduced Ifna and Ifng expression. 53 We propose a broad indirect effect of IL-33 on IFN-bdependent immune events. Inhibiting IL-33 restored ifnb expression in structural and immune cells along with parallel increased IFN-g production by T cells and increased granzyme A expression in lung parenchyma. The exact mechanism by which IL-33 inhibits IFN-b awaits further studies. The IL-33-mediated reduced cytotoxic antiviral processes in lung parenchyma might also relate to the reduced ifnb expression. It is unclear whether the increased cytotoxicity seen on BAL and NETosis relate directly to IL-33 or to the enhanced viral loads (Fig 4, I) .
IL-33 release is enhanced very early after viral challenge and drives all cellular increases in BAL fluid, lung tissue, and mLNs within 2 days after infection. Interestingly, the high levels of IL-33 release are also paralleled by de novo Il33 transcription. Despite this release, 4 days after the viral challenge, aST2 did not influence the recruitment of all cell populations in lung parenchyma to the same magnitude. This indicates that 4 days after infection, mechanisms other than IL-33 contribute to exacerbations, which suggests that intervention therapies aimed at IL-33 might be optimal only shortly after infection.
aST2 reduced IL-33 levels, which is suggestive of autocrine IL-33 production. IL-33 was released predominantly in cell-dense areas reflecting areas of acute inflammation (Fig 2, C and D) . 30 The enhanced expression of IL-33 in asthma and after viral inoculation was shown in mice and asthmatic patients, although the source of IL-33 in patients appeared to be ciliated ECs with some positive IL-33 staining within basal cells, whereas in mice IL-33 was found in alveolar type II cells. These findings contrast with IL-33 staining in basal cells in patients with chronic obstructive pulmonary disease, 30 which suggest that the pathogenic role of structural cells differs between asthmatic patients and patients with chronic obstructive pulmonary disease.
Our studies show that in experimental asthma IL-33 promotes T H 2-like responses, but on influenza infection, there was no increase or decrease in T H 2-like responses despite enhanced IL-33 levels. ILC2s are considered to amplify T H 2 airway inflammation in response to IL-33, but ILC2 counts were not increased during X31-induced exacerbations and importantly did not correlate with IL-33 concentration and exacerbation severity. For the first time, we demonstrate that ILC2s and NCR 1 ILC3s were the only prednisone-resistant subsets in experimental chronic asthma. Therefore we speculate that ILC2s still release the T H 2 mediators that maintain T H 2 inflammation during asthma exacerbation. It would be of interest to further clarify this in vivo.
ILC2s and ILC3s are plastic subsets, and they could potentially turn into ILC1s on influenza infection, but numbers of these cells were not increased either. 54, 55 To address these issues, it would be of interest to assess the kinetics of cytokine production by innate lymphoid cell subsets ex vivo. Despite reduction of T H 2-promoting OX40L expression on CD11b 1 cDCs and moDCs and reduced numbers of T H 2-polarized CD4 1 T cells by aST2, T H 2 cytokine levels in the airway were not affected until day 8 after infection. Therefore the T H 2-like responses appear quite stable because neither an increase nor a reduction in IL-33 levels changed the T H 2-like responses. We consider it likely that a reduction in T H 2-like responses could occur at later time points, such as once the IL-33-dependent DCs programming has been reset. In another study with a different mouse strain (BALB/c), however, blocking IL-33 signaling in HDM-sensitized mice was unsuccessful because it did not affect lung inflammation. This failure perhaps is due to the very high HDM doses and prototypical T H 2-type mouse strains used in that study. 26 Because IL-33 and TSLP are known to synergize, we addressed this in the present study.
22,23 IL-33 was necessary and sufficient for driving increased AHR, viral replication, and innate and adaptive leukocyte responses. In this model TSLP was redundant in worsening airway inflammation, but it synergized with IL-33 to drive AHR only at a late time point (day 8 after infection; Figs 1, 3, and Fig 4, A) . TSLPactivated DCs promote differentiation of naive CD4
1 T cells to a T H 2 phenotype and expansion of CD4
1 T H 2 memory cells in an OX40L-dependent manner. 56, 57 Given our findings, we speculate that the marked aST2-induced OX40L downregulation on DCs dampened a clear effect, at least on CD4 1 T cells, by aST2
1 and aTSLP. Although a previous study showed that OX40L signaling did not affect T-cell homing, 58 more recently, in an atopic dermatitis2like model 59 and in sarcoma models, 60 TSLP derived from structural cells and DC-OX40L were found to orchestrate trafficking of innate leukocytes and CD4 1 T cells toward the lymph nodes. Whether this can explain the accumulation of cells in lymph nodes, as observed by blocking TSLP, remains to be determined. Surprisingly, aTSLP treatment alone resulted in further aggravated AHR. We propose that TSLP-induced signal transducer and activator of transcription 3 phosphorylation-dependent activation in airway smooth muscle cells synergizes with IL-33-mediated signal transducer and activator of transcription 5 activation, leading to increased airway smooth muscle contraction. 61 Nevertheless, mechanisms by which TSLP controls AHR remain unexplained. In addition, TSLP exerted a robust chemoattractant function for many myeloid and lymphoid populations, postulating a role for TSLP in regulating hematopoietic cell egress from lymphoid organs and recirculation for homeostatic clearance in the bone marrow (Fig 3, E, and see Fig E6) . These findings unveiled the role of TSLP per se in the context of experimental asthma exacerbation. However, we cannot exclude that blocking TSLP in association with other treatments (ie, inhaled corticosteroids) results in abrogation of airway inflammation or normalizes AHR. Recently, it was demonstrated that blocking TSLP in asthmatic patients treated with long-acting b-agonists and high doses of inhaled corticosteroids resulted in lower rates of clinically significant asthma exacerbations than in those who received placebo. 62 In conclusion, we have shown that IL-33 drives virus-induced asthma exacerbations mainly by dampening innate and adaptive T H 1 and cytotoxic responses. This leads to exaggerated inflammatory responses reflected by increased levels of mediators and numbers of inflammatory cells and NETosis. It is unclear whether greater or prolonged viral loads underlie these exaggerated inflammatory responses, but we have excluded a role for T H 2-like inflammatory responses. The IL-33/ST2 axis represents a potential pharmacologic target to control severe virus-induced asthma exacerbations. Because of the fundamental role of IL-33 in resolution of sepsis, viral and helminthic infections, angiogenesis, vasculature and cardiac repair, and central nervous system injury recovery, 18 ,63-66 interventions of short duration rather than prolonged interventions are an option. Given the acute IL-33 responses during virus-induced exacerbation, local short-term treatment in the airways in patients with stable asthma to reduce IL-33 levels or acute therapy after the very first signs of infection should be contemplated.
METHODS Treatments
Anti-mouse ST2 and anti-mouse TSLP mAbs were generated and selected by Amgen after extensive in vitro and in vivo testing. Previously unpublished tests for the efficacy of anti-TSLP included a bone marrow-derived DC bioassay measuring inhibition of TSLP-induced CCL17/thymus and activation-regulated chemokine production and an assay measuring inhibition of TSLP-induced proliferation of a pro-B-cell line stably transduced with murine TSLP receptor. Neutralization of IL-33 and TSLP signaling was achieved by administering 150 or 350 mg of antibody in 100 mL, respectively, by means of intraperitoneal injection, where indicated. As a proper control for the neutralizing antibodies administered with single and double blocks, a group of mice received 250 mg of mouse IgG 1 in the absence of anti-ST2 and 250 mg of rat IgG 1 in the absence of anti-TSLP.
Specimen collection and primary cell isolation
Blood (0.5-1 mL) was collected by means of cardiac puncture (preferably right ventricle) in the presence of heparin as an anticoagulant. Blood samples were subjected to density gradient separation on Ficoll-Paque Plus (ratio 1:1; GE Healthcare Life Sciences, Buckinghamshire, United Kingdom) and centrifuged. After centrifugation, the PBMC layer was collected and washed in Hank balanced salt solution with phenol red without calcium and magnesium (Lonza, Basel, Switzerland). For BAL fluid collection, mice were cannulated through the trachea, and right lung lavage was performed by instilling and retrieving 1 mL of sterile saline. Recovered BAL fluid was centrifuged at 260g for 10 minutes at 48C, and supernatants were stored at 2808C until further use, whereas the pellet was immediately resuspended in 0.2 mL of sterile saline. Cell counts were then determined for each BAL fluid sample by using Trypan blue staining, and differential cell counts were performed on cytospin preparations stained with modified Giemsa stain. For each BAL fluid sample, the cellular subset phenotypes were determined by using flow cytometry.
Lungs were perfused with 5 mL of sterile saline through the pulmonary circulation by means of catheterization of the right heart ventricle to remove the intravascular pool of cells. Then the left lung (not subjected to BAL fluid), spleen, and mLNs were removed. The left lung was minced with iridectomy scissors to prepare a lung homogenate; lungs and mLNs were enzymatically digested for 1 hour at 378C with Collagenase type III (200 U/mL Worthington Biochemical, Lakewood, NJ) and DNAse I (100 U/mL; grade II from bovine pancreas, Sigma) in RPMI 1640. Pulmonary, splenic, and lymph node cell suspensions were obtained by grinding the tissue through 70-mm nylon sieves, and red blood cells were lysed with ammonium chloride buffer. Cell counts were then performed before staining for flow cytometric analysis. The cell suspension was lysed with Greenberger buffer (75 mmol/L NaCl, 7.5 mmol/L Tris, 0.5 mmol/L MgCl 2 , 0.5 mmol/L CaCl 2 , 0.5% Triton X-100, 4 mg/mL 4-[2-aminoethyl] benzenesulfonyl fluoride, 50 mg/mL Na 2 -EDTA, 10 ng/mL Pepstatin A, and 10 ng/mL leupeptin, pH 7.4) for 30 minutes on ice, followed by centrifugation at 680g for 10 minutes. Supernatants were stored at 2808C until further use.
Mouse tracheal EC transcriptome analysis
Samples were analyzed for il33, tslp, and ifnb expression by using the Affymetrix GeneChip Mouse Gene 2.1 ST array (Affymetrix). Raw data were quality assessed and normalized by using robust multiarray average normalization, and differential gene expression analysis was performed with the Array Studio software (Omicsoft, Research Triangle Park, NC). il33 values are expressed as log 2 -transformed intensity values and fold change (FC) between indicated groups with statistical comparisons based on a general linear model. The false discovery rate (FDR) was used to address multiple test correction for genes with an FC of greater than 2 or less than 2. Some genes had an FDR of less than 0.05 but did not reach an FC of greater than 2 or less than 2. In the gene set variation analysis 1-way ANOVA was used to analyze the ES differences among group means and post hoc analysis by using the Tukey test. g:Profiler was used for pathway analysis of differential gene and protein expression. Statistically significant differences between groups (FDR < 0.05) are indicated.
Human PBEC transcriptome analysis
Human PBECs were collected by means of bronchial brushing during bronchoscopy and dissolved in 1 mL of TRIzol (Invitrogen, Thermo Fischer Scientific), and RNAwas isolated according to the manufacturer's instructions and purified by using the Nucleospin RNA XS extraction kit (MachereyNagel, Duren, Germany). Quality and concentration of the samples were assessed by using a fragment analyzer. Sample preparation was performed according to the protocol NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB #7420S/L). Briefly, oligo-dT magnetic beads were used to isolate mRNA from total RNA. cDNA synthesis was performed after mRNA fragmentation. This was used for ligation with sequencing adapters, followed by PCR amplification of the resulting product. The quality and yield after sample preparation were measured with a fragment analyzer. The size of the resulting products was consistent with the expected size distribution between 300 and 500 bp. Raw data were sampled and mapped to the annotated genomic reference to evaluate the quality of the library preparation and kits used. Mapping positions were classified as intragenic, exonic, intergenic, intronic, and rRNA. Clustering and DNA sequencing were performed according to the manufacturer's protocol by using the Illumina NextSeq 500. A concentration of 1.6 pmol/L was used as input. Reads were trimmed for adapter sequences by using Trimmomatic v0.30 before alignment. Presumed adapter sequences were removed from the read when the bases matched a sequence in the adapter sequence set (TruSeq adapters) with 2 or less mismatches and an alignment score of at least 12. The reference of Homo_sapiens.GRCh37.75 was used to align the reads. Mapping to the reference sequence was done with a short reader aligner based on Burrows-Wheeler transformation. The default mismatch rate of 2% (3 mismatches in a read of 150 bases) was used.
Frequencies of the reads mapped on the transcript were determined as counts, which are used as inputs for downstream analysis. Additionally, reads per kilobase of exon per million reads mapped and fragments per kilobase of exon per million reads mapped values were calculated. Read counts were loaded into the DESeq package v1.26.0, a statistical package within the R platform to determine differentially expressed genes. The R platform is specifically for small sample size and overdispersion and uses an expression curve model based on a negative binomial distribution and local regression to estimate the relationship between the mean and variance of each gene. Image analysis, base calling, and quality checks were performed with the Illumina data analysis pipeline RTA v2.4.11 and bcl2fastq software v2.17 (Illumina, San Diego, Calif). The entire data set will be published separately (A. Ravi).
IL-33 immunostaining
Paraffin-embedded lung tissue was cut into 3-mm sections and subjected to heat-induced epitope retrieval in a pretreatment module (PT-link; Dako Cytomation) with citrate buffer (pH 6) before immunohistochemical staining. Staining was performed at room temperature in an automated IHC robot (AutostainerPlus; Dako Cytomation). For IL-33 staining, sections were sequentially blocked with endogenous enzyme block (EnVision FLEX Peroxidase-Blocking Reagent; Dako) and serum-free protein block (Dako) before incubation with a primary goat anti-mouse IL-33 antibody (R&D Systems). Next, sections were incubated with a Polymer/horseradish peroxidase-linked secondary antibody (FLEX K8010, Dako), followed by incubation with 3,39-diaminobenzidine substrate-chromogen solution for 10 minutes and counterstaining with Mayer hematoxylin (blue nuclei). Finally, sections were dehydrated through an ethanol series, cleared in xylene, and mounted with Pertex (HistoLab). High-resolution digital images of the stained sections were generated by using a combined bright-field and epifluorescence digital slide scanner unit (Olympus VS120; Olympus, Center Valley, Pa).
IL-33 immunoreactivity was analyzed by using an automated computerized image analysis (CCV Software; Medetect AB, Lund, Sweden). Briefly, the brown 3,39-diaminobenzidine-stained IL-33 immunoreactivity was captured by using preset color segmentation threshold values. The tissue outline and total area of lung tissue were calculated (excluding alveolar air spaces and the luminal compartment of blood vessels and conducting airways). Next, lung IL-33 levels were calculated and expressed as the proportion of firm lung tissue occupied by means of positive IL-33 staining. Alterations in IL-33 expression was also investigated by individual cell data plots in which dots (x,y coordinates) for each IL-33-immunereactive cell was plotted on the tissue section graph and color coded according to the mean intensity of IL-33 staining.
Flow cytometric analysis and sorting
For phenotypic analysis of eosinophils (CD11b Mice were administered doses of anti-ST2 (aST2) and anti-TSLP (aTSLP) 3 days before X31 infection and every 3 days in combination to achieve double blockade. The control group received isotype control antibodies; on days 4, 6, and 8, all mice were analyzed. D, C57BL/6J mice were chronically (intranasally) exposed 5 days a week for 5 consecutive weeks to HDM and infected (intranasally) with influenza virus A/X31 H3N2 (X31) on day 29 of the sensitization schedule. Mice were administered doses of aST2 3 days before X31 infection and every 3 days. The control group received an isotype control antibody. E, C57BL/ 6J mice were infected (intranasally) with influenza virus A/X31 H3N2 (X31) and administered doses of aST2 3 days before X31 infection and every 3 days. The control group received an isotype control antibody; on days 4, 6, and 8, all mice were analyzed. PenH, Enhanced pause. (Fig E9, A) and lung parenchyma (Fig E9, B) are shown.
Data are representative of 4 replicates of independent experiments with 4 mice per group and represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for comparison between HDM/X311aST2 and HDM/ X31 groups, 2-way ANOVA followed by the Bonferroni posttest. Fig E11, A, Data represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups, 2-way ANOVA followed by the Bonferroni posttest. (B) Data represent means 6 SEMs: *P < .05, **P < .01, and ***P < .001 for the comparison between indicated groups, t test. 
